re: accumulation Agreed Harvett,And that's why it's at $2m...

re: accumulation Agreed Harvett,

And that's why it's at $2m market cap and not $200m - the risk that the changes they are currently making to the Oraline product doesn't permit them into the Asian markets. I guess that's where Chairman Howard Digby can assist and also these guys:

http://www.asx.com.au/asxpdf/20131118/pdf/42kxv56rkpgv14.pdf


But the new potential acquisition mitigates the risk of complete loss of shareholder value from the above failing.

The EV is already pretty low anyway assuming they still have about $1.5m cash.

It's a company with a new board and new direction but trying to make the most out of previous IP which is not going to be expensive and can easily reach commercialization quickly with proper management and contacts, but whilst pursuing new more exciting projects (ie therapeutics). Seems a sensible way to restore some shareholder value. I don't see much downside from this price but there's a lot of upside. You only need to look at what the new board have announced in the last few months to see they are having a good go.